Evidence map›Paper›PMID 25072037›Full record

ReviewFrontiers in pediatrics2014

Potential therapeutic use of the ketogenic diet in autism spectrum disorders.

Eleonora Napoli, Nadia Dueñas, Cecilia Giulivi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Diet in treatment of autism spectrum disorders.Frontiers in neuroscience · 2022
    Review
  15. Review
  16. Review
  17. Article
  18. The Role of Microbiome, Dietary Supplements, and Probiotics in Autism Spectrum Disorder.International journal of environmental research and public health · 2020
    Review
  19. Article
  20. Translation deregulation in human disease.Nature reviews. Molecular cell biology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Eleonora NapoliDepartment of Molecular Biosciences, University of California Davis , Davis, CA , USA.
Nadia DueñasDepartment of Molecular Biosciences, University of California Davis , Davis, CA , USA.
Cecilia GiuliviDepartment of Molecular Biosciences, University of California Davis , Davis, CA , USA ; Medical Investigations of Neurodevelopmental Disorders (M. I. N. D.) Institute , Sacramento, CA , USA.
University of California, Davis · USNeuroDevelopment Center · US

Funding

THE CHARGE STUDY: CHILDHOOD AUTISM RISKS FROM GENETICS AND THE ENVIRONMENT - ADMINISTRATIVE SUPPLEMENTR01ES015359 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HERTZ-PICCIOTTO, IRVA · 2007 to 2019
$13.8M
UC Davis Center for Children's Environmental Health (CCEH)P01ES011269 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI VAN DE WATER, JUDY A. · 2001 to 2018
$12.5M
Autism Risk, Prenatal Environmental Exposures, and Pathophysiologic MarkersR01ES020392 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HERTZ-PICCIOTTO, IRVA, OZONOFF, SALLY · 2011 to 2015
$9.0M
NIEHS NIH HHS P01 ES011269NIEHS NIH HHS R01 ES015359NIEHS NIH HHS R01 ES020392
6 · The paper itself

Abstract

The ketogenic diet (KGD) has been recognized as an effective treatment for individuals with glucose transporter 1 (GLUT1) and pyruvate dehydrogenase (PDH) deficiencies as well as with epilepsy. More recently, its use has been advocated in a number of neurological disorders prompting a newfound interest in its possible therapeutic use in autism spectrum disorders (ASD). One study and one case report indicated that children with ASD treated with a KGD showed decreased seizure frequencies and exhibited behavioral improvements (i.e., improved learning abilities and social skills). The KGD could benefit individuals with ASD affected with epileptic episodes as well as those with either PDH or mild respiratory chain (RC) complex deficiencies. Given that the mechanism of action of the KGD is not fully understood, caution should be exercised in ASD cases lacking a careful biochemical and metabolic characterization to avoid deleterious side effects or refractory outcomes.

Indexed as

autism spectrum disordersbioenergeticsdietary interventionepilepsyketogenic dietmitochondriaoxidative stress

Identifiers

PMID25072037
PMCPMC4074854
OpenAlexW2025395276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.